Психиатрия Психиатрия и психофармакотерапия им. П.Б. Ганнушкина
№03 2021

Список исп. литературыСкрыть список

1. Быков Ю.В., Беккер Р.А., Морозов П.В. Эффективность карипразина
в лечении шизофрении, особенно с преобладанием негативной симп-
томатики. Психиатрия и психофармакотерапия им. П. Б. Ганнушкина.
2018;5:27–37.
2. Беккер РА, Быков ЮВ, Морозов ПВ. Карипразин как социализирую-
щий препарат при шизофрении (Обзор литературы). Психиатрия и
психофармакотерапия им. П. Б. Ганнушкина. 2020;02:16–24.
3. Ágai-Csongor É, Domány G, Nógrádi K, et al. Discovery of cariprazine
(RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.
Bioorg Med Chem Lett. 2012;22:3437–3440.
4. American Psychiatric Association. Diagnostic and statistical manual of the
American psychiatric association. 5th ed. 2013. Arlington, VA: American
Psychiatric Association.
5. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia
and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.
Schizophr Res. 2006;83(2–3):185–192.
6. Barth V, Need AB, Tzavara ET, et al. In vivo occupancy of dopamine D3
receptors by antagonists produces neurochemical and behavioral effects of
potential relevance to attention-deficit-hyperactivity disorder. J Pharmacol
Exp Ther. 2013;344(2):501–510.
7. Calabrese JR, Keck PE, Jr, Starace A, et al. Efficacy and safety of low-and
high-dose cariprazine in acute and mixed mania associated with bipolar I
disorder: a double-blind, placebo-controlled study. J Clin Psychiatry.
2015;76(3):284–292.
8. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics,
and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug
Metab Toxicol. 2013;9(2):193–206.
9. Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine
in inadequate responders to antidepressants: a randomized, double‐
blind, placebo‐controlled study in adult patients with major depressive
disorder. J Clin Psychiatry. 2016;77(3):371‐378.
10. Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, doubleblind,
placebo-controlled evaluation of the safety and efficacy of cariprazine
in patients with bipolar I depression. Am J Psychiatry. 2016;173(3):271-281.
11. Durgam S, Earley W, Lu K et al. Global improvement with cariprazine in
the treatment of bipolar I disorder and schizophrenia: A pooled post hoc
analysis. Int J Clin Pract. 2017;71(12):e13037.
12. Durgam S, Starace A, Li D et al. The efficacy and tolerability of cariprazine
in acute mania associated with bipolar I disorder: a phase II trial. Bipolar
Disord. 2015;17(1):63–75.
13. Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression:
a randomized double-blind placebo-controlled phase 3 study. Am
J Psychiatry 2019; 176: 439–448.
14. Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in
bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar
Disord. 2020;22(4):372-384.
15. Fava M, Durgam S, Earley W, et al. Efficacy of adjunctive low‐dose cariprazine
in major depressive disorder: a randomized, double‐blind,
placebo‐controlled trial. Int Clin Psychopharmacol. 2018;33(6):312‐321.
16. Forest Laboratories Inc. Forest Laboratories Inc Gedeon Richter Plc. announce
positive Phase IIb topline results for cariprazine as adjunctive therapy
in the treatment of major depressive disorder [press release] 2014 (b).
17. Forest Laboratories Inc. Forest Laboratories Inc. Gedeon Richter Plc Announce
positive Phase IIb topline results for cariprazine for the treatment
of bipolar depression [press release] 2014 (a).
18. Gao Y, Peterson S, Masri B, et al. Cariprazine exerts antimanic properties
and interferes with dopamine D2 receptor ß-arrestin interactions. Pharmacol
Res Perspect. 2015;3(1):e00073.
19. Johnson M, Kozielska M, Pilla Reddy V, et al. Dopamine D2 receptor occupancy
as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic
modeling approach. Pharm Res. 2014;31(10):2605–2617.
20. Kapás M, Mészáros GP, Yu B, et al. (P.3.c.051) Comparison of the pharmacokinetic
behaviour of RGH-188 in schizophrenic patients and healthy volunteers.
Eur Neuropsychopharmacol. 2008;18(Suppl 4):S433.
21. Kapur S, Remington G, Jones C, et al. High levels of dopamine D-2 receptor
occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry.
1996;153(7):948–950.
22. Kapur S, Zipursky R, Roy P et al. The relationship between D2 receptor occupancy
and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology
(Berl) 1997;131(2):148–152.
23. Ketter TA, Sachs GS, Durgam S, et al. The safety and tolerability of cariprazine
in patients with manic or mixed episodes associated with bipolar I disorder:
a 16-week open-label study. J Affect Disord 2018; 225: 350–356.
24. Kirschner N, Gémesi LI, Vastag M, et al. In vitro metabolism of RGH-188;
Presented at the 10th European International Society of the Study of Xenobiotics
(ISSX), Meeting; May 18–21, 2008.
25. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine
D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist
antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol
Exp Therap. 2010;333(1):328–340.
26. Kiss B, Némethy Z, Fazekas K, et al. Preclinical pharmacodynamic and pharmacokinetic
characterization of the major metabolites of cariprazine.Drug
Des Develop Ther. 2019;13:3229-3248.
27. Laszlovsky I, Németh G, Mészáros P, et al. (P.3.c.053) Dopamine D2/D3 receptor
occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic,
in healthy volunteers. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S455.
28. Madras BK. History of the discovery of the antipsychotic dopamine D2 receptor:
a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci.
2013;22(1):62–78.
29. McIntyre RS, Masand PS, Earley W, et al. Cariprazine for the treatment of
bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J
Affect Disord 2019; 257: 600–606.
30. McIntyre RS, Suppes T, Earley W, et al. Cariprazine efficacy in bipolar I depression
with and without concurrent manic symptoms: post hoc analysis
of 3 randomized, placebo-controlled studies. CNS Spectr. Epub ahead of
print 2 October 2019.
31. Mészáros GP, Kapás M, Borsos M, et al. (P.3.c.047) Pharmacokinetics of RGH-
188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic,
in healthy subjects. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S451–S452.
32. Newman-Tacredi A. The importance of 5HT1A receptor agonism in antipsychotic
drug action: rationale and perspectives. Curr Opin Investig Drugs.
2010;11(7):802–812.
33. Nordström AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor
occupancy in relation to antipsychotic drug effects – a double-blind PET
study of schizophrenic-patients. Biol Psychiatry. 1993;33(4):227–235.
34. Papp M, Gruca P, Lasoń-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I.
Attenuation of anhedonia by cariprazine in the chronic mild stress model
of depression. Behav Pharmacol. 2014;25(5–6):567–574.
35. Parker P. The 2021-2026 World Outlook for Bipolar Disorder Drugs. ICON
Publishing, 2021 (E-publication ahead of print). E-book ASIN:
B0863TKL3P. 299 p.
36. Pásztor Mészáros G, Agai-Csongor E, Kapaś M. Sensitive LC-MS/MS methods
for the quantification of RGH-188 and its active metabolites, desmethyl-
and didesmethyl-cariprazine in human plasma and urine. J Pharm
Biomed Anal. 2008;48(2):388–397.
37. Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN. Efficacy of
cariprazine in bipolar I depression across patient characteristics: a post hoc
analysis of pooled randomized, placebo-controlled studies. Int Clin Psychopharmacol.
2021;36(2):76–83.
38. Patel MD, Vieta E, Calabrese J, Whelan J, Tohen M. Efficacy of cariprazine
on functioning in patients with bipolar depression: post hoc analysis of a
randomized, placebo-controlled trial. Poster to be presented at: American
Psychiatric Association Annual Meeting; May 2021; virtual.
39. Periclou A, Phillips L, Ghahramani P, Kapás M, Carrothers T, Khariton T.
Population Pharmacokinetics of Cariprazine and its Major Metabolites. Eur
J Drug Metab Pharmacokinet. 2021;46(1):53-69.
40. Potkin S, Keator D, Mukherjee J, et al. (P.1.e.028) Dopamine D3 and D2 receptor
occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol.
2009;19(Suppl 3):S316.
41. Ridray S, Griffon N, Mignon V, et al. Coexpression of dopamine D1 and D3
receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite
and synergistic functional interactions. Eur J Neurosci. 1998;10:1676–1686.
42. Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Update on schizophrenia
and bipolar disorder: focus on cariprazine. Neuropsychiatr Dis Treat.
2016;12:1837-42.
43. Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of
acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase
III trial. J Affect Disord 2015; 174: 296–302.
44. Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D2 and
D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate,
cariprazine (RGH-188), in monkey brain measured using positron
emission tomography. Psychopharmacology (Berl) 2011;218(3):579–587.
45. Sheynikhovich D, Otani S, Arleo A. The role of tonic and phasic dopamine
for long-term synaptic plasticity in the prefrontal cortex: a computational
model. J Physiol Paris. 2011;105(1–3):45–52.
46. Simpson EH, Winiger V, Biezonski DK, Haq I, Kandel ER, Kellendonk C.
Selective overexpression of dopamine D3 receptors in the striatum disrupts
motivation but not cognition. Biol Psychiatry. 2013;76(10):823–831.
47. Sokoloff P, Diaz J, Levesque D, et al. Novel dopamine receptor subtypes as
targets for antipsychotic drugs. Ann NY Acad Sci. 1995;757:278–292.
48. Stahl SM, Laredo S, Morrissette DA. Cariprazine as a treatment across the bipolar
I spectrum from depression to mania: mechanism of action and review
of clinical data. Ther Adv Psychopharmacol. 2020;10:2045125320905752.
49. Stahl SM, Morrissette DA. Mixed mood states: baffled, bewildered, befuddled
and bemused. Bipolar Disord 2019; 21: 560–561.
50. Stahl SM, Morrissette DM, Faedda G, et al. Guidelines for the recognition
and management of mixed depression. CNS Spectr 2017; 22: 203–219.
51. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and
Practical Applications. Cambridge university press, 2013. 626 p. ISBN 978-
1107686465.
52. Stahl SM. Stahl’s Essential Psychopharmacology: Case studies. Volume 2.
Cambridge university press, 2015. 504 p. ISBN 978-1107607330.
53. Vieta E, Calabrese JR, Whelan J, Tohen M, Earley W. The efficacy of cariprazine
on function in patients with bipolar depression: a post hoc analysis
of a randomized controlled trial. Curr Med Res Opin. 2021.
54. Vraylar [package insert]. Madison, NJ: Allergan USA, Inc; 2019.
55. Citrome L. Cariprazine for acute and maintenance treatment of adults with
schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr
Dis Treat. 2018;14:2563-2577.
56. Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D3-receptor-
preferring partial agonist, blocks phencyclidine-induced impairments
of working memory, attention set-shifting, and recognition memory in the
mouse. Psychopharmacology (Berl) 2013;226(1):91–100.
57. Zohar J, Nutt DJ, Kupfer DJ, et al. A proposal for an updated neuropsychopharmacological
nomenclature. Eur Neuropsychopharmacol 2014; 24:
1005–1014.